ArticleThe AAPS journal2025
Impacts of Antibody Structure and Mixtures on Receptor Signaling for Antibody-Dependent Cellular Cytotoxicity.
Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer.Oncology research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antibody-Dependent Cellular Cytotoxicity (ADCC) is a key mechanism of action for humoral immune response, which is important for clinical antibodies such as trastuzumab and cetuximab. The level of ADCC is dependent on multiple properties such as antibody isotype, Fab affinity, epitope, and geometry in the immune synapse. Here, we integrated computational simulations with experiments to analyze the impacts of several key factors on ADCC, including binding affinity, target expression, hinge flexibility, and antibody valency. The kinetic model was adapted to simulate antibody cross-linking between tumor and immune-reporter cells, followed by signal activation. Given the complexity of the interactions between cells and the formation of the immunological synapse, we fitted the effective on-rates within the synapse that are hard to determine a priori. With minimal fitting, the model successfully replicated the trends of immune activation for a series of trastuzumab structural mutants. The simulations demonstrated that antibody variants with a higher likelihood of monovalent target binding, such as single-arm antibodies, as well as those with low Fab affinity and reduced hinge flexibility, increased signaling. The model was able to capture the efficacy of mixtures of antibodies with different Fc domains, which are relevant for combination treatments such as trastuzumab and pertuzumab. Interestingly, the fraction of receptors blocked with antibody combinations was more important than total receptor expression, implying restrictions on diffusion of free receptors in the synapse. Overall, the simulations showed close agreement with experimental observations, providing a tool to interpret the ADCC results and guide the design of antibody therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.